A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib

Lenvatinib is an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, as well as platelet-derived growth factor receptor α, RET, and KIT. At present, lenvatinib is used in the treatment of thyroid cancer and renal...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura-Tsuchiya, Reiko, Sasaki, Eisaku, Nakamura, Izumi, Suzuki, Satoshi, Kawana, Satoshi, Okouchi, Chiyo, Fukushima, Toshihiko, Hashimoto, Yuko, Suzuki, Shinichi, Saji, Shigehira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836208/
https://www.ncbi.nlm.nih.gov/pubmed/29515414
http://dx.doi.org/10.1159/000486569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836208/
https://www.ncbi.nlm.nih.gov/pubmed/29515414
http://dx.doi.org/10.1159/000486569

Ejemplares similares